Cullinan Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CGEM Nasdaq 2834 cullinantherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cullinan Therapeutics, Inc.

Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data - Mar 13th, 2026 11:11 pm
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight - Mar 10th, 2026 3:31 pm
Cullinan Therapeutics: Q4 Earnings Snapshot - Mar 10th, 2026 5:23 am
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 10th, 2026 5:00 am
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference - Mar 7th, 2026 10:03 pm
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - Feb 24th, 2026 5:00 am
Cullinan Therapeutics Touts 2026 “Defining Year” as T-Cell Engager, Zipalertinib Catalysts Near - Feb 19th, 2026 6:12 pm
TheStreet Pro Analysts Say, “It’s a Stock Picker’s Market – Here Are 4 to Consider” - Feb 19th, 2026 5:17 am
Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum - Feb 13th, 2026 12:09 am
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Feb 5th, 2026 5:00 am
Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength - Jan 23rd, 2026 6:55 am
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - Jan 14th, 2026 1:30 am
Adimab Reports Strong Partnering Year for 2025 - Jan 12th, 2026 12:57 pm
Cullinan Therapeutics provides corporate update, anticipated 2026 milestones - Jan 9th, 2026 5:15 am
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones - Jan 8th, 2026 5:00 am
Will Cullinan Therapeutics (NASDAQ:CGEM) Spend Its Cash Wisely? - Dec 17th, 2025 9:17 am
Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates - Dec 15th, 2025 9:10 pm
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting - Dec 8th, 2025 8:31 am
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia - Dec 1st, 2025 5:00 am
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations - Nov 20th, 2025 5:00 am